Migraine
Pipeline by Development Stage
Drug Modality Breakdown
Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.
Key Trends
- Extreme market concentration: 68% of spending driven by one FXa inhibitor product
- Psychiatric and migraine therapies emerging as secondary growth drivers
- High clinical trial activity (8,279 trials) signals continued pipeline development
Career Verdict
Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 68% | Launch | Stable | 14.9yr |
| 2 | INVEGA SUSTENNA (paliperidone palmitate) | Johnson & Johnson | $1.8B | 7% | Peak | Stable | 4.6yr |
| 3 | BRILINTA (ticagrelor) | AstraZeneca | $692M | 3% | Peak | Stable | 10.1yr |
| 4 | NUPLAZID (pimavanserin tartrate) | Acadia Pharmaceuticals | $596M | 2% | Peak | Stable | 10.8yr |
| 5 | INVEGA TRINZA (paliperidone palmitate) | Johnson & Johnson | $530M | 2% | Peak | Stable | 15.4yr |
Drug Class Breakdown
market-defining single product
stable mature class
niche but stable
specialty indication focus
emerging growth segment
stable with LOE risk
diverse small products
Career Outlook
StableNeurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.
Breaking In
Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.
For Experienced Professionals
Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.
In-Demand Skills
Best For
Hiring Landscape
Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.
Top Hiring Companies
By Department
Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.
On Market (8)
Approved therapies currently available
Competitive Landscape
57 companies ranked by most advanced pipeline stage
+27 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 76,763 patients across 50 trials
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
Treatment Patterns Among US Veterans Using Remote Electrical Neuromodulation (REN) for Migraine Treatment
Nerivio Efficacy Under High-Frequency Use
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
Nerivio Efficacy by Time of Treatment Onset
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies
A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache
Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
Real World Effectiveness of Eptinezumab in Participants With Migraine
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
Biomarker and Genetic Predictors of Erenumab Treatment Response
A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
Ticagrelor Therapy for RefrACTORy Migraine Study
Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine
Migraine Treatment Satisfaction With Treximet Versus Concomitant 2 Aleve and Imitrex
Rizatriptan in Acute Treatment of Migraine in Patients With Unilateral Trigeminal-autonomic Symptoms.
"Completeness of Response" Following Treatment With Treximet™ for Migraine
Rizatriptan 10 MG RPD in the Treatment of Acute Migraine
Two Rizatriptan Prescribing Portions for Treatment of Migraine
Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine
A Trial to Study of the Effects of Eletriptan 40mg on Mild vs Moderate to Severe Pain Intensity of Migraine
Prospective Survey of Menstrual Migraine & Prevention With Eletriptan
ZAP, US. Zomig for Appropriate for Primary Care
A Study Comparing the Effectiveness and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) Versus Placebo for the Treatment of Acute Pain From a Migraine Headache
Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy
Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs
A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants
Study of Wireless Nerve Stimulation in the Treatment of Chronic Migraine
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine
Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)
A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
Related Jobs in Neurology
Medical Science Liaison/Senior Medical Science Liaison, Migraine (Southeast)
Medical Science Liaison/Senior Medical Science Liaison, Migraine (Northwest Region)
Medical Science Liaison/Senior Medical Science Liaison, Migraine (South Region)
Senior Buyer
Head of Marketing
Scientific Instrumentation Software Engineer
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.